News from ASCO 2022 - Part 1 Gyn Cancer/ Survivorship Posters

The last post I wrote I was very excited to be going to Chicago to attend #ASCO22 Annual meeting. I had to change those plans after I started experiencing vertigo. My PCP advised me to not fly. So I cancelled my hotel and flight and switched gears to attend the meeting virtually.  

The set up for the virtual meeting this year allowed some sessions to be viewed live and other sessions would be available to watch On Demand later for those virtual attendees. The tech was not cooperating with me on Friday, most of Saturday until late on Sunday. I appreciate all the time that ASCO staff and IT spend with me trying to resolve my issue. In the future I will not use " in my name. 

Because of that delay, I will report on the posters which I could access first and then the other sessions. 

POSTERS  Gyn Cancer Research 

Interesting process for dispersing chemotherapy in the abdomen of women with OC

Gyn Poster session #ASCO22
Abs 4424 Poster 403
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy
PIPAC in # OVCA
A different IP process to treat OC.
Better response rate and improved QOL#gyncsm pic.twitter.com/Hguv2lRyir

— Dee Sparacio (@womenofteal) June 4, 2022

How sensitive is rucaparib in women with OC who do not have homologous recombination deficiency

Gyn poster #ASCO22 Coleman
Abs 5544 Efficacy/ safety rucaparib maintenance ARIEL3 with platinum-sensitive, recurrent OC not associated w/ HRD
Rucaparib maintenance reduced risk of progression in pts with ovarian carcinomas, including those not associated with HRD.#gyncsm pic.twitter.com/yv7DdGbLN5

— Dee Sparacio (@womenofteal) June 4, 2022

Next Generation Sequencing in OC

BRAF, PIK3R1, NOTCH3,MET, and/or ATR correlated with shorter PFS 

ATM, RB1, CDKN2A, FGFR1, and/or FGFR2 associated with improved PFS 

Gyn poster #ASCO Foster Ab5545 P 424 Clinical implications of tumor-based next-generation sequencing in ovarian cancer
Mutation patterns correlate to survival #gyncsm
most frequent alterations were TP53, PIK3CA, and NF1 mutations; and CCNE1 amplification pic.twitter.com/pjT8Qugg6Q

— Dee Sparacio (@womenofteal) June 4, 2022

Clear Cell Genomic Analysis

Gyn posters #ASCO22
Ab 5548 Poster 427 Haribhakti,
Genomic analysis of clear cell carcinoma
CCCs do not separate by organ of origin beyond renal versus extra-renal. TP53, ARID1A, and PIK3CA were the most frequently altered genes in non-renal CCC. #gyncsm pic.twitter.com/xzM3KjdUyw

— Dee Sparacio (@womenofteal) June 4, 2022

KELIM  - Algorithm that is calculated with 6 to 7 CA-125 values measured during the first 100 days after chemotherapy start

Suggests that bevicizumab is mainly effective in patients w/ poorly chemosensitive diseases. Highest benefit from bevacizumab in PFS and OS were high-risk diseases (stage IV, or incompletely.

Gyn poster #ASCO22 You
Ab 5553 P 432
ID of ovarian cancer who are experiencing the highest benefit from bev in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation
Study
Trial confirms outcomes of ICON-7 trial 1/2 #gyncsm

— Dee Sparacio (@womenofteal) June 4, 2022

Possible  biomarker test for OC uses extracellular vesicles

Gyn Poster #ASCO22
Ab 5542 P 421
Extracellular vesicle-based (EV)biomarker assay for the detection of early-stage ovarian cancer.
EV-based platform technology Mercy HALO distinguishes HGSOC from benign in the blood compared to CA 125 #gyncsm 1/2 pic.twitter.com/Rp2nCwcidw

— Dee Sparacio (@womenofteal) June 4, 2022

Posters Survivorship

 1 Frailty, 2 Cooling Caps, 3 Yoga, 4 Acupuncture for Neuropathy

I could access the page for #ASCO22 survivorship posters. My favorites:
Prevalence of frailty for middle-aged and older adults starting a new line of systemic cancer treatment: Is age just a number? 1/4
Pergolotti Ab 12054 P300
patient reported Geriatric Assess similar frailty pic.twitter.com/3LSsm4eBqk

— Dee Sparacio (@womenofteal) June 5, 2022

 

3/4 #ASCO22 Yoga intervention on distress indicators among diverse women /gyn , gi, &thoracic cancers Hanvey AB 12129
Mindfulness-based yoga intervention was associated with sig reductions in depressive symptoms, anxiety, & psychological distress related to Fear of Recurrence pic.twitter.com/UCaiDQNTeT

— Dee Sparacio (@womenofteal) June 5, 2022

 

4/4 #ASCO22 A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.
Dooley Ab TPS12125
electroacupunture (EA) versus sham acupuncture (SA)
Accrual completion 2024
Clinical trial information: NCT04917796. pic.twitter.com/fUJoajX6P8

— Dee Sparacio (@womenofteal) June 5, 2022

 Stay tuned over the next few days for additional information on gyn cancer specific sessions. 

Dee

Every Day is a Blessing!

Day 15 A Month of Teal : Chemotherapy Side Effects and Cold Caps

The chemotherapy women take to treat ovarian cancer may cause a number of side-effects including

• Nausea*
• Loss of appetite
• Mouth sores
• Increased chance of infection
• Bleeding or bruising easily
• Vomiting*
• Hair loss**
• Fatigue
• Constipation
• Diarhea

* ASCO recently released a guideline for prescribing anti-nausea medication called Antiemetics:ASCO Clinical Practice Guideline Update. You may read the full text here> http://ascopubs.org/doi/10.1200/JCO.2017.74.4789 

**Recently, the FDA has approved a cold cap (DigniCap and Paxman cooling systems,) that can be worn during chemotherapy which prevents  hair loss. See this ACS page for more information.
https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/hair-loss/cold-caps.html


Be sure to notify your doctor or nurse if you should experience any of these side effects.

I'll be back on Sept 18th to share more information with you. 

Dee
Every Day is a Blessing!